- Home
- UAMY vs TRDA Comparison
UAMY vs TRDA Comparison
Compare UAMY & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- TRDA
- Stock Information
- Founded
- UAMY 1968
- TRDA 2016
- Country
- UAMY United States
- TRDA United States
- Employees
- UAMY N/A
- TRDA N/A
- Industry
- UAMY Metal Fabrications
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- TRDA Health Care
- Exchange
- UAMY Nasdaq
- TRDA Nasdaq
- Market Cap
- UAMY 316.8M
- TRDA 264.5M
- IPO Year
- UAMY N/A
- TRDA 2021
- Fundamental
- Price
- UAMY $3.35
- TRDA $6.54
- Analyst Decision
- UAMY Strong Buy
- TRDA Strong Buy
- Analyst Count
- UAMY 4
- TRDA 3
- Target Price
- UAMY $3.38
- TRDA $25.67
- AVG Volume (30 Days)
- UAMY 7.3M
- TRDA 151.8K
- Earning Date
- UAMY 08-08-2025
- TRDA 08-12-2025
- Dividend Yield
- UAMY N/A
- TRDA N/A
- EPS Growth
- UAMY N/A
- TRDA N/A
- EPS
- UAMY N/A
- TRDA 0.61
- Revenue
- UAMY $18,865,900.00
- TRDA $172,220,000.00
- Revenue This Year
- UAMY $270.45
- TRDA N/A
- Revenue Next Year
- UAMY $104.06
- TRDA N/A
- P/E Ratio
- UAMY N/A
- TRDA $10.73
- Revenue Growth
- UAMY 97.46
- TRDA 5.74
- 52 Week Low
- UAMY $0.31
- TRDA $6.12
- 52 Week High
- UAMY $4.19
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- UAMY 56.29
- TRDA 43.47
- Support Level
- UAMY $3.28
- TRDA $6.22
- Resistance Level
- UAMY $3.82
- TRDA $6.63
- Average True Range (ATR)
- UAMY 0.34
- TRDA 0.36
- MACD
- UAMY 0.07
- TRDA 0.02
- Stochastic Oscillator
- UAMY 58.58
- TRDA 28.09
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.